Albert Einstein College of Medicine researchers report that the composition of people's gut bacteria may explain why some of them suffer life-threatening reactions after taking a key drug for treating metastatic colorectal ...
Nov 1, 2017
1
322
The drug aflibercept (trade name: Zaltrap) has been approved in Germany since February 2013 in combination with a certain chemotherapy for adults with metastatic colorectal cancer in whom chemotherapy with oxaliplatin could ...
Jul 11, 2013
0
0
(HealthDay)—For elderly patients with metastatic colorectal cancer (mCRC), scores on the Mini-Mental State Examination (MMSE) and Instrumental Activities of Daily Living (IADL) were predictive of severe toxicity or unexpected ...
Mar 14, 2013
0
0
A University of Rhode Island researcher has discovered that the weight-loss drug orlistat, known by the brand names Xenical and Alli, inhibits a key enzyme that may lead to "severe toxicity of internal organs such as the ...
Dec 10, 2012
0
0
A Cancer Research UK funded trial will offer new treatments for children and adults with a form of muscle cancer called rhabdomyosarcoma that has returned or does not respond to current treatments.
Oct 22, 2012
0
0
A new drug treatment could offer hope to patients with advanced colorectal cancer who were intolerant of or did not respond to standard treatments, according to an article published in the Lancet Oncology.
Aug 27, 2012
0
0
(HealthDay) -- Zaltrap (ziv-afilbercept) has been approved by the U.S. Food and Drug Administration in combination with a FOLFIRI chemotherapy regimen for adults with advanced metastatic (spreading) colorectal cancer, the ...
Aug 4, 2012
0
0
(HealthDay) -- For patients with irinotecan-refractory metastatic colorectal cancer (CRC), dose escalation of cetuximab is well tolerated and may improve response and disease control rates, but patients experience more grade ...
Jul 5, 2012
0
0
(HealthDay) -- Continuing use of bevacizumab (Avastin) in combination with second-line chemotherapy improves overall survival (OS) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC) who ...
Jun 5, 2012
0
0
Researchers from the University of Zurich have found a cellular brake that protects cancer cells from chemotherapy -- and they demonstrate which medication can be used to render it inoperative. Their study published in the ...
Mar 5, 2012
0
0
Irinotecan (Camptosar, Pfizer; Campto, Yakult Honsha) is a drug used for the treatment of cancer.
Irinotecan prevents DNA from unwinding by inhibition of topoisomerase 1. In chemical terms, it is a semisynthetic analogue of the natural alkaloid camptothecin.
Its main use is in colon cancer, in particular, in combination with other chemotherapy agents. This includes the regimen FOLFIRI, which consists of infusional 5-fluorouracil, leucovorin, and irinotecan.
Irinotecan received accelerated approval by the U.S. Food and Drug Administration (FDA) in 1996 and full approval in 1998. During development, it was known as CPT-11.
This text uses material from Wikipedia, licensed under CC BY-SA
